Chicago Equity Partners LLC Acquires New Stake in Diplomat Pharmacy Inc (DPLO)
Chicago Equity Partners LLC acquired a new stake in Diplomat Pharmacy Inc (NYSE:DPLO) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 60,515 shares of the company’s stock, valued at approximately $1,215,000.
Several other large investors have also recently made changes to their positions in DPLO. PNC Financial Services Group Inc. increased its position in shares of Diplomat Pharmacy by 46.7% in the 2nd quarter. PNC Financial Services Group Inc. now owns 8,779 shares of the company’s stock valued at $130,000 after purchasing an additional 2,794 shares during the last quarter. First Allied Advisory Services Inc. purchased a new position in shares of Diplomat Pharmacy in the 2nd quarter valued at $183,000. SG Americas Securities LLC purchased a new position in shares of Diplomat Pharmacy in the 3rd quarter valued at $191,000. Piedmont Investment Advisors LLC purchased a new position in shares of Diplomat Pharmacy in the 3rd quarter valued at $216,000. Finally, Fox Run Management L.L.C. purchased a new position in shares of Diplomat Pharmacy in the 4th quarter valued at $244,000. 69.87% of the stock is currently owned by institutional investors.
In other Diplomat Pharmacy news, CFO Atul Kavthekar acquired 2,000 shares of the stock in a transaction on Monday, November 20th. The shares were bought at an average cost of $15.00 per share, with a total value of $30,000.00. Following the transaction, the chief financial officer now owns 2,000 shares of the company’s stock, valued at approximately $30,000. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jeffrey G. Park acquired 3,000 shares of the stock in a transaction on Monday, November 20th. The shares were acquired at an average cost of $15.46 per share, for a total transaction of $46,380.00. Following the completion of the transaction, the director now directly owns 7,640 shares in the company, valued at approximately $118,114.40. The disclosure for this purchase can be found here. Insiders have acquired a total of 15,000 shares of company stock worth $228,780 over the last three months. 30.20% of the stock is currently owned by insiders.
A number of research firms recently commented on DPLO. Deutsche Bank downgraded shares of Diplomat Pharmacy from a “buy” rating to a “hold” rating and increased their target price for the company from $22.00 to $29.00 in a research report on Friday, February 2nd. BidaskClub downgraded shares of Diplomat Pharmacy from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, October 17th. Mizuho set a $16.00 target price on shares of Diplomat Pharmacy and gave the company a “hold” rating in a research report on Tuesday, October 24th. Needham & Company LLC increased their target price on shares of Diplomat Pharmacy from $23.75 to $24.00 and gave the company a “buy” rating in a research report on Wednesday, November 8th. Finally, Credit Suisse Group raised shares of Diplomat Pharmacy from an “underperform” rating to a “neutral” rating and set a $28.00 target price on the stock in a research report on Thursday, January 25th. Seven analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. Diplomat Pharmacy has an average rating of “Hold” and a consensus target price of $22.85.
About Diplomat Pharmacy
Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.
Want to see what other hedge funds are holding DPLO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Diplomat Pharmacy Inc (NYSE:DPLO).
Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.